IL-22 Dimer Neuroprotection STAT3 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's are ineffective in halting disease progression and often come with adverse side effects, with no established method to address the degeneration of neurons.
Innovation Solution
The use of interleukin-22 (IL-22) or its dimer form, which has a prolonged serum half-life and enhanced biological activity, to treat and prevent neurodegenerative diseases by activating STAT3 in neurons, protecting dopaminergic neurons, and reducing apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments such as levodopa are used for Parkinson's disease, then neurotransmitter levels are replenished, but the disease progression cannot be halted and adverse side effects occur
Solution Approach 1:
The patent introduces a novel therapeutic agent (compound of formula I) that acts as an intermediary to activate the STAT3 signaling pathway in neurons. This mediator provides neuroprotection by preventing neuronal apoptosis and degeneration, thereby addressing the fundamental limitation of current treatments that only supplement neurotransmitters without protecting neurons from progressive damage.
Solution Approach 2:
The patent changes the therapeutic parameter from neurotransmitter replacement to STAT3 pathway activation. By targeting the signaling pathway that controls neuronal survival and protection, the treatment shifts from symptomatic management to disease-modifying therapy that can halt progression while maintaining neurotransmitter function.
2Ease of operation
If current symptomatic treatments are used for neurodegenerative diseases, then some symptoms are relieved, but the degeneration and apoptosis of neurons continue
Solution Approach 1:
The compound of formula I serves as a protective intermediary that intervenes in the pathological process of neuronal degeneration. By activating STAT3, it creates a protective effect against apoptosis and degeneration, thereby addressing the harmful factors that current symptomatic treatments fail to prevent.
Solution Approach 2:
The treatment performs preliminary protective action by activating STAT3 before irreversible neuronal death occurs. This preventive mechanism protects neurons from degeneration and apoptosis, addressing the underlying pathology rather than merely treating symptoms after damage has occurred.
3Reliability
If frequent administration of treatment is performed, then therapeutic effect is maintained, but treatment complexity and burden increase
Solution Approach 1:
The patent introduces a dimer form of the therapeutic compound that dynamically extends the drug's half-life in serum. This dynamic modification allows the drug to maintain effective concentrations for longer periods, reducing administration frequency while ensuring continuous therapeutic effect and neuroprotection.
Solution Approach 2:
The patent uses a dimer composite structure (formula II) where two monomer units are linked together. This composite structure increases molecular weight and serum stability, thereby extending half-life and reducing the frequency of administration needed to maintain therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IL-22 dimer effectively inhibits neuronal loss, improves neurological function, and prolongs treatment efficacy, offering a more effective approach to managing neurodegenerative diseases with reduced frequency of administration.
Implementation Method 1
IL-22 exerts its biological function by binding IL-22R1 receptor and IL-10R2 receptor
Implementation Method 2
activating STAT3 in neurons, protecting dopaminergic neurons, and reducing apoptosis
Data Source
AI summary
This invention discloses the uses of IL-22 in the treatment and prevention of a nerve damage disease or a neurodegenerative disease. In particular, the invention discloses the uses of IL-22 or IL-22 dimers as follows: (i) can protect neurons to recover the functions of injured neurons after ischemic nerve damage in animals in vivo, thus enabling effective treatment of nerve damage diseases, (ii) can significantly inhibit the loss of dopaminergic neurons in substantia nigra in PD model animal, enhance the functions of dopaminergic neurons, significantly reduce neuronal apoptosis in hippocampus, improve learning and memory capacity of AD model rats, and effectively prevent neuronal loss, thereby enabling more effective treatment of neurodegenerative diseases.